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Lack of T-cell reactivity to allogeneic mesenchymal stem cells in a baboon model of bone repair M. Kevin, K. Beggs, M. Archambault, A. Moseley, R. Deans, A. Smith, S. Peter (Baltimore, USA) Due to their ability to differentiate into a variety of mesenchymal lineages including bone, mesenchymal stem cells (MSCs) should be useful for the repair or regeneration of damaged tissue. A universal allogeneic donor of MSCs would be ideal for this purpose. Results from previous cell culture studies in multiple species have demonstrated that MSCs do not elicit a proliferative T cell response from allogeneic T cells. Furthermore, MSCs have been shown to suppress the mixed lymphocyte reaction (MLR) which is mediated by alloreactive T cells, mediators of transplant rejection. To determine whether allogeneic MSCs would elicit a T cell response in vivo and to determine the efficacy of these MSCs in bone regeneration, baboon MSCs were implanted in various matrix materials in segmental gaps created in the fibulae of allogeneic recipient animals. At various times after implantation, the baboons were bled, the peripheral blood mononuclear cells (PBMCs) were isolated, and the PBMCs were cultured with irradiated PBMCs from the MSC donor animals. The cultures were assessed for allogeneic T cell responses at time points chosen to determine primary (day 7 harvest) and secondary (day 3 harvest) responses. Control cultures consisted of PBMCs cultured in medium alone, with autologous irradiated PBMCs, and with 3rd party PBMCs. The results showed that allogeneic MSCs did not elicit a systemic T cell response in the recipients since T cell proliferative responses against donor cells did not increase between pre-implantation and post-implantation bleeds. The absence of recipient priming by allogeneic MSCs was further demonstrated by primary response kinetics of T cell proliferative responses. These responses were comparable in magnitude to 3rd party responses. These results corroborate our earlier in vitro findings showing that MSCs are not immunogenic and they suggest that a universal donor of MSCs should be practical for tissue repair.
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Reassessment of ABO-incompatibility in hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is performed routinely across the ABO-barrier. Current concepts do not stipulate a negative effect of the ABO barrier on survival and ABO compatible or incompatible transplants are considered as equivalent. However, this dogma is based on studies performed almost 20 years ago and since then, overall survival and GvHD rates have clearly improved and reassessment appears warranted. In order to do so, we performed a retrospective analysis of 562 consecutive patients receiving HSCT. Among these, 361 were ABO-identical, 98 had a minor, 86 a major, and 17 a bidirectional incompatibility. As previously reported, hemolysis occured more frequently in patients with ABO-incompatibility as compared to ABO identical HSCT (46% vs. 16%, p=0.001) and patients with major or bidirectional ABO-incompatibility also received more RBC transfusions. In addition, patients with minor ABO-incompatibility had a higher risk to develop acute GvHD (odds ratio=3.09, p=0.0024). In contrast, the relapse rate was not associated with . Using a multivariate Cox regression analysis, patients with bidirectional ABO-incompatibility had a significantly higher mortality risk compared to those with ABO-identity (hazard ratio=2.3, CI 1.28-4.17, p=0.005, see figure) . In conclusion, ABO-incompatibility seems to be a significant risk factor after HSCT. It is associated with a higher incidence of hemolysis. Even more important is the finding that it may also significantly affect the incidence of acute GvHD and survival. These data suggest, that ABO antigens can act as minor histocompatibility antigens. Although these findings have to be confirmed in larger prospective studies, the current view that ABO-incompatibility is irrelevant in HSCT should be reconsidered.
Previous studies in dogs indicated that depletion of CD6-positive cells from the marrow graft prevented graft-versus-host disease (GVHGD) across one DLA-haplotype difference (Schumm et al. 1994) . Moreover CD6-negative marrow cells contained NK cells (Guenther et al. 1994) and suppressed the generation of cytotoxic T-cells (CTL) against DLA-mismatched targets. In this study we analyzed the immune phenotype of suppressor cells in human marrow and blood stem cell concentrates (PBSC). PBSC were depleted with the anti-CD6 mAb M-T411 (Connex) and magnetic beads (Dynal) using the MaxSep cell separator (Nexell). These preparations suppressed the MLR in HLA-mismatched combinations by 40% as compared to undepleted marrow and PBSC that suppressed by 22%. After depletion with the CD6-immmunomagnetic beads we detected 0-3% of CD6-pos., 0.1-5% CD4-pos., and 2.4-13% CD8-pos. cells by flow cytometry. Further characterization was attempted by CD34-selection and CD8-selection (MiniMACS, Miltenyi). CD34-positive cells did not suppress MLR, whereas CD8-positive cells contained in the CD6-negative fraction suppressed MLR by 38%. In contrast the CD8-negative fraction of CD6-negative PBSC did not suppress MLR. CD8-selected, CD6-depleted PBSC are depleted of NK-cells and B-cells. Therefore the phenotype of suppressor cells is CD6-negative and CD8-positive. We have transplanted 21 patients in advanced phases of leukemia with marrow and CD6-depleted PBSC from HLA-haplotype mismatched donors. Engraftment was successful in 18 evaluable patients and GVHD was mild in 12 patients. The results are promising and future attempts will be made to perform the transplants in less advanced stages of the disease.
